PRTG

Portage Biotech Inc., operating through its various subsidiaries, focuses on the discovery and advancement of novel pharmaceutical and biotechnological products. The company's extensive pipeline includes several key therapeutic candidates and platforms. Among these are IMM60, an activator for iNKT cells; IMM65, a specialized PLGA-nanoparticle integrated with a NY-ESO-1 peptide vaccine; and INT230-6, which is currently in Phase I/II clinical trials for addressing solid tumors. Additionally, their portfolio features STING, a small molecule designed to bind to the stimulator of interferon genes in cancer; CellPorter, a platform utilizing cell-permeable peptides derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology aimed at re-establishing immune balance after acute vital organ injury, such as acute kidney injury. The company also dedicates efforts to nanolipogel technology for its applications in immuno-oncology. It is developing antibodies against a novel T-cell for potential use as both monotherapy and combination therapy in treating solid and haematological malignancies. Furthermore, Portage Biotech is advancing antibodies that target the inflammatory tumor microenvironment and tumor-infiltrating immune cells, alongside an investigational FOXO4-P53 modulator and a C-RAF inhibitor. Portage Biotech Inc. is headquartered in Tortola, British Virgin Islands.